Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised medicine.
Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions (56 drug combinations x 20 replicates) on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments. This research, incorporating fundamental science alongside clinical expertise at Aachen University Hospital, was led by EMBL group leader Christoph Merten and Julio Saez-Rodriguez, former group leader at EMBL-EBI and now Professor at Heidelberg University.
Small biopsies, many drugs
Directly testing multiple cancer drugs on biopsies – parts of the tumour which have been taken from a patient – is a powerful way to discover which drugs work best, and for whom. This is because depending on the specific tumour characteristics, cancer therapies can be more effective in some people than others. However, large-scale patient specific drug screenings have so far been limited by the small biopsy size that can typically be obtained from patients. That is why in the current paper, the team developed a miniaturised device which can test more drugs on a limited number of cells.
The research team initially tested 56 drug combinations on two different human cancer cell types grown in the lab. Drug combinations which killed both types of cancer cells were thought to be potentially toxic and thus unsafe for further testing. However, some drug combinations which targeted and killed only one type of cancer cell were found to be more effective than standard clinical therapies which only use one drug. These results were highly reproducible and could be validated in mouse models of human cancer.
Subsequently, cells from four cancer patient biopsies were applied to the microfluidic device and different drug combinations were tested. “We found that each individual cancer responded best to a different combination of drugs, highlighting the urgent need for patient-specific therapies,” says Federica Eduati, joint first author on the paper alongside Ramesh Utharala who designed and developed the microfluidic device.
“Before we transfer this technology into the clinics, we need to repeat these experiments in larger-scale mouse studies to understand which types of cancer this technology works best in,” says Christoph Merten. “Still, this is an exciting ‘proof of principle’ collaboration between scientists and clinicians, and we have shown that these tests can be run quickly and for less than $150 USD per patient.”
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- CarThera and KIYATEC Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Canceron November 18, 2019 at 4:08 pm
“We believe that this clinical collaboration has the potential to help us accelerate and deliver on the long-awaited promise of personalized medicine for these deserving patients.” Both companies will ...
- BRIEF—CarThera and Kiyatec collaborate on personalized medicine for glioblastomaon November 18, 2019 at 9:23 am
US biotech Kiyatec and France’s CarThera have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma, a highly ...
- Personalized Medicine Market By Product, Geography and Forecast 2019 – 2026on November 13, 2019 at 2:34 am
Nov 13, 2019 (Market Prediction via COMTEX) -- Acumen Research and Consulting has announced the addition of the “Personalized Medicine Market” report to their offering. The Personalized Medicine ...
- Global Personalized Medicine Market Advancement, Size, Growth, Access and Forecast 2019-2025 | Key Players – Abbott, Amgen, Astellas Pharma and Moreon November 13, 2019 at 1:48 am
QY Research offers an overarching research and analysis-based study on the global Personalized Medicine market, covering growth prospects, market development potential, profitability, supply and ...
- Personalized Medicine Market Comprehensive Insights Of Recent Developmentson November 11, 2019 at 10:42 pm
The report is readily available and can be dispatched immediately after payment confirmation.
- Interview with Wei Jian Goh of Craft Health on Personalized Medicine and Nutritionon November 8, 2019 at 12:16 am
Wei Jian Goh’s startup Craft Health makes personalized medicine and nutrition possible. The startup is one I’m very envious of as I’ve had a lot of ideas in this area for years. Ideas are nothing ...
- Personalized Medicine Market Market Drivers 2019 - Industry Analysis, Regional Outlook and Segmented Analysis 2026on November 6, 2019 at 7:46 am
Nov 06, 2019 (Market Insight Reports via COMTEX) -- VMR has recently announced the addition of a new research report, titled 'Personalized Medicine Market Report 2019', offers a clear understanding of ...
- Entrepreneurs should focus on evidence to create businesses that provide personalized medicineon October 29, 2019 at 7:52 am
NEWPORT BEACH, California — Panelists at the OCTANe Medical Technology Innovation Forum discussed what entrepreneurs need to focus on when they develop a new business that looks to provide ...
- The global personalized medicine (PM) market size is expected to reach USD 3.18 trillion by 2025 registering a CAGR of 10.6% over the forecast periodon October 21, 2019 at 11:55 am
Personalized Medicine Market Size, Share & Trends Analysis By Product (Personalized Medical Care, Therapeutics, Personalized Nutrition & Wellness), By Region (Asia Pacific, Europe, North America), And ...
via Bing News